These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30030117)

  • 21. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
    Tian T; Ruan M; Yang W; Shui R
    Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma.
    Lu J; Chen XM; Huang HR; Zhao FP; Wang F; Liu X; Li XP
    Head Neck; 2018 Jun; 40(6):1245-1253. PubMed ID: 29493822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
    Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
    Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
    Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.
    Tang Y; He Y; Shi L; Yang L; Wang J; Lian Y; Fan C; Zhang P; Guo C; Zhang S; Gong Z; Li X; Xiong F; Li X; Li Y; Li G; Xiong W; Zeng Z
    Oncotarget; 2017 Jun; 8(24):39001-39011. PubMed ID: 28380458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer.
    Zhang XL; Jiang C; Zhang ZX; Liu F; Zhang F; Cheng YF
    Oncol Res Treat; 2014; 37(9):480-4. PubMed ID: 25231688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
    Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
    Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
    Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
    Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.
    Hoesli R; Birkeland AC; Rosko AJ; Issa M; Chow KL; Michmerhuizen NL; Mann JE; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; McHugh JB; Brenner JC; Spector ME
    Oral Oncol; 2018 Feb; 77():83-89. PubMed ID: 29362129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients.
    Fuchs TL; Sioson L; Sheen A; Jafari-Nejad K; Renaud CJ; Andrici J; Ahadi M; Chou A; Gill AJ
    Am J Surg Pathol; 2020 Apr; 44(4):536-544. PubMed ID: 31743129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.
    Zhang R; Liao X; Zhang B; Huang X; Qin G; Kong X; Xie Y; Mo Y; Dai J; Gan C; Luo Z; Lu J; Jiang W
    Pathol Res Pract; 2024 Jan; 253():154936. PubMed ID: 38006840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity.
    Zhang G; Xu Y; Zhang S; Zhou H
    Biomed Res Int; 2020; 2020():9756732. PubMed ID: 31998801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.
    Jiang R; Zou X; Hu W; Fan YY; Yan Y; Zhang MX; You R; Sun R; Luo DH; Chen QY; Huang PY; Hua YJ; Guo L; Chen MY
    Tumour Biol; 2015 Sep; 36(10):7775-87. PubMed ID: 25944165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
    Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
    Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma.
    Zhao J; Guo C; Xiong F; Yu J; Ge J; Wang H; Liao Q; Zhou Y; Gong Q; Xiang B; Zhou M; Li X; Li G; Xiong W; Fang J; Zeng Z
    Cancer Lett; 2020 May; 477():131-143. PubMed ID: 32061950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.